Drug intelligence / Profile preview

WAY265506

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

WAY265506 is a **small molecule** that acts as an inhibitor of the *Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway*. It is primarily used as a **tool compound** in research. In published studies, WAY265506 is shown to inhibit MAPK/ERK signaling, which leads to upregulation of TXNIP and a reduction in microRNA-372 (miR-372) expression in colorectal cancer cell lines. Its mechanism is useful in studying the regulation of miR-372 expression and potentially in modulating cancer biology through the MAPK/ERK pathway[1].

Beyond the preview

Go deeper on WAY265506.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WAY265506.

Explore the full profile